Evaxion has released promising three-year data on its EVX-01 immunotherapy, demonstrating durable immune responses and sustained disease control in patients with advanced melanoma. This latest data highlights EVX-01’s potential as a transformative treatment option for melanoma, a cancer with limited long-term therapies. The study results indicate that EVX-01 not only stimulates a robust immune reaction but also contributes to prolonged disease stabilization over an extended period. By leveraging Evaxion’s AI-driven approach to personalized cancer vaccines, the therapy targets specific tumor neoantigens to enhance patient outcomes. These findings offer renewed hope for advanced melanoma patients seeking innovative and effective treatment strategies. Evaxion’s continued research and development in immuno-oncology position EVX-01 as a noteworthy candidate in the evolving landscape of cancer therapeutics. The announcement underscores the significance of personalized immunotherapies in improving survival rates and quality of life for melanoma patients.
Quiver QuantitativeNew data shows Job-ready Graduates reforms significantly boosting enrolment
October 23, 2026
Recent enrolment data reveals that the Job-ready Graduates reforms are effectively improving higher education outcomes in Australia. The reforms, aimed at aligning university courses with